关节专业
您的位置: 骨科在线关节专业学术园地-典型病例列表页
骨质疏松性椎体压缩骨折手术病例
74245
李xx,男,78岁 骨质疏松性椎体压缩骨折 T11、T12、L1
0
足踝病例
74224
女性,65岁,双侧拇外翻3年,行走足底痛,第二跖骨头下硬皮,右侧为甚。
0
人工全膝关节置换术后下肢静脉血栓病例报告
71416
患者,女,74岁,以“双侧人工表面全膝关节置换术后40天,双小腿肿胀10天。”主诉入院。患者40天前因“双膝骨性关节炎”行“双侧人工表面全膝关节置换术”,术后伤口愈合良好,双膝活动度良好,患者双下肢轻度肿胀,无明显疼痛,皮肤不红,行走无明显影响。10天来患者无明显诱因出现双侧小腿肿胀,活动后加重,休息后无明显缓解,再次来院治疗。既往患高血压病4年,糖尿病2年,口服药物控制血压、血糖平稳。患胃溃疡1年。
0
人工全膝关节置换术后下肢静脉血栓病例报告
71404
患者,女,74岁,以“双侧人工表面全膝关节置换术后40天,双小腿肿胀10天。”主诉入院。患者40天前因“双膝骨性关节炎”在我院行“双侧人工表面全膝关节置换术”,术后伤口愈合良好,双膝活动度良好,患者双下肢轻度肿胀,无明显疼痛,皮肤不红,行走无明显影响。10天来患者无明显诱因出现双侧小腿肿胀,活动后加重,休息后无明显缓解,再次来院治疗。既往患高血压病4年,糖尿病2年,口服药物控制血压、血糖平稳。患胃溃疡1年。
0
脊柱肿瘤典型病例
71247
患者,男,48岁,腰3椎体肿瘤,行后路全脊椎整块切除。
0
关于骨形态发生蛋白试验争论的更多启示
23881
翻译者: 广东省人民医院:顾宏林,尹东       骨科研究学会成员在一个关于如何避免在新产品和新治疗发展过程中走弯路的临床研究论坛中,将重组人骨形态发生蛋白-2(rhBMP-2)列入议程。尽管最近各种报道指出产业资助试验的结果遭到抨击,“标签外使用”药物仍广受关注。     克利夫兰市的临床医师Thomas Mroz博士提出一些和“标签外使用药物”(也称内科医师直接使用的药物)相关的议题。     BMP在1965年由Marshall Urist博士发现,但直到2002年,它的一种形式——rhBMP-2才被美国FDA批准使用,而且只能和LT-Cage(美敦力公司)用于单节段的腰椎前路融合术中,而在其它任何手术——包括颈胸椎融合、后外侧、后路和经椎间孔腰椎融合术中的使用仍未被临床试验认可。FDA章程和其它适用法律允许内科医师根据其灵通的药物判断患者的最大利益,以此开出或授权任何合法市场推广这种“标签外使用药物”。     史坦佛大学的Eugene J. Carragee博士提出这些药物很多都是标签外使用并且大剂量使用。Mroz 博士引用了其提出的问题,反问道:“如果该类药物有效,那问题是什么?”其并发症包括神经炎性反应、逆行射精和脊神经根炎、感染和伤口问题、致癌或促癌。 Mroz博士从销售数据中估计2011年大约有165,000名患者使用rhBMP-2,而且今年还将有148,000人使用。他估计2/3为“标签外使用”使用。例如,最近一项对Spineline杂志读者的调查显示,大部分支持rhBMP-2的医生将其用于各种“适应症外”的手术。     获得该产品安全性和有效性数据的常用方法是文献回顾,但Mroz博士指出这种综述是基于少部分入组研究的患者,而不是实际上众多使用该药物的患者。另外考虑的问题是研究设计、报道、实践相当大的不均一性以及Carragee博士概括出的利益冲突问题。     “注册和保险数据库很有可能用于随访大量的患者”,Mroz博士说。理论上的优点包括潜在的可收集资料和在临床应用中方法技术应用的跟进。该数据库还将使跨时间和跨区域的适应症监控以及结果对照成为可能。然而他也指出,该数据库的管理复杂且昂贵。“设计很简单,但实施却很复杂,”他说。 更多透明度     医学博士、工商学管理硕士Kevin J. Bozic在对rhBMP-2产业试验评价的概述中,第一次指出产业介入的优点是它能提供资金、基础设施和承担创新风险。     “内科医生中的创新者很自然的不愿承担风险,而产业却能为其创新提供提供资金、基础设施和并愿意承担风险,因此使之获益。”他说。Bozic医师同时也指出器械产业为临床试验提供很多必需的支持。     但是,围绕临床试验的产业资金投入仍受到很多关注,包括产业对研究者选择的影响、研究设计和结果的宣传。     研究者的产业选择会导致研究结果的偏差,Bozic医师指出,接受了咨询和使用费的外科医生常常会因为经济冲突而影响他们的客观性,从而影响临床试验的结果。这样就会影响到那些阅读关于产业资助临床试验的结果文章的人,而“思想领袖”的意见往往会对临床医生造成很大影响。 无论是否真的存在,公众都认为产业资助的试验存在偏差。根据其发布的结果,Bozic医师指出产业资助的研究是专有的,并不需要出版和传播,许多临床试验从不发表,就算在发表的试验中,也不是将所有的数据公布。     Bozic医师主持了耶鲁大学数据公开分析计划(YODA)的临床指导委员会,会议试图解决临床研究的产业资助方面的一些关注问题。该计划由研究中rhBMP-2的生产商美敦力公司赞助,其既定目标是“通过促进对药物和设备优劣相关数据独立的分析和传播机制,来增加透明度并增强公众对产业资助临床试验的信心。”Terry Stanton During a clinical research forum on ways to avoid wrong turns in the development of new products and therapies, members of the Orthopaedic Research Society included the issue of recombinant human bone morphogenetic protein–2 (rhBMP-2). Although various aspects of reporting the results of industry-sponsored trials have come under fire recently (See “Lessons Learned: What the BMP Trials Controversy Has Taught Us” in The Daily Edition—AAOS Now, Feb. 9, 2012), concerns about “off-label” use were also raised. Thomas Mroz, MD, of the Cleveland Clinic, addressed some general issues associated with off-label—also called “physician-directed”—use. BMP was discovered in 1965 by Marshall Urist, MD, but it was not until 2002 that one form, rhBMP-2, was approved by the U.S. Food and Drug Administration (FDA)—for use, and only in one-level anterior lumbar interbody fusion with an LT-Cage (Medtronic). Its use in any other procedure—cervical and thoracic fusions, posterolateral, posterior and transforaminal lumbar interbody fusions—is off-label. FDA regulations and other applicable laws recognize that physicians may prescribe or administer any legally marketed product for an off-label use, according to the physician’s well-informed medical judgment for the best interest of the patient. Asking rhetorically, “If it works, what’s the problem?” Dr. Mroz cited the numerous problems previously detailed by Eugene J. Carragee, MD, of Stanford University, noting that many of them occurred in off-label usage and with high-dose usage. These complications included neuroinflammatory reactions of retrograde ejaculation and radiculitis, infection and wound problems, and cancer promotion or carcinogenicity. Extrapolating from sales data, Dr. Mroz estimated that about 165,000 patients received rhBMP-2 in 2011, and 148,000 will do so this year. He estimated that two thirds of this usage is off-label. A recent survey of Spineline’s readership, for example, found that most of the responding surgeons use rhBMP-2 for various off-label fusion procedures. The common way to obtain data about the safety and efficacy of the product is to review the literature, but Dr. Mroz noted that such a review will be based on a relatively small number of patients involved in studies, versus the large number who actually receive the product. Another consideration is the considerable heterogeneity in study design, reporting, and execution, as well as the conflict-of-interest problems outlined by Dr. Carragee. Registries and insurance databases have great potential for following large numbers of patients, Dr. Mroz said. Theoretical merits include prospectively collected data and the ability to follow implementation of techniques and technologies in clinical practice. Such databases would also enable indications to be monitored across regions and over time and outcome comparisons to be made across regions and over time. However, he noted, such database management is complex and expensive. “The design is easy. Implementation is complex,” he said. More transparency Presenting an overview of the evaluation of industry-reviewed trials in the context of rhBMP-2, Kevin J. Bozic, MD, MBA, first noted that merits of industry’s involvement include its providing a source of capital, infrastructure, and risk for innovation. “Physician-innovators, who tend to be risk-averse by nature, benefit from close collaboration with industry, which provides the capital, infrastructure, and willingness to take risk that are necessary for this type of innovation,” he said. Dr. Bozic also noted that the device industry provides much-needed support for clinical trials. However, a number of concerns surround industry funding of clinical trials, including industry influence over selection of investigators, study design, and the dissemination of results. Industry selection of investigators can lead to biased interpretation of results, Dr. Bozic said, noting that surgeons who receive consulting and royalty fees often have financial conflicts that may influence their objectivity in interpreting the results of a clinical trial. This issue can affect those who read manuscripts describing the results of industry-funded clinical trials, and the opinions of “thought leaders” often carry outsized influence with clinicians. The public perception of bias is also an issue involved in industry funding, whether or not there is actually bias in the study. In terms of sharing results, Dr. Bozic noted that industry-funded research is proprietary, with no requirement for publication or dissemination. Many clinical trials that are conducted are never published; even among published trials, not all data are revealed. Dr. Bozic chairs the Clinical Steering Committee of the Yale Open Data Access project (YODA), which is seeking to address some of the concerns with industry sponsorship of clinical research. Funded by Medtronic Inc., which manufactures the rhBMP-2 product used in the studies, the project’s stated goal is to “increase transparency and enhance the public trust in industry-funded clinical trials by facilitating the independent assessment and dissemination of data relevant to the benefits and harms of drugs and devices.” Disclosure information: Dr. Carragee—Intrinsic Therapeutics, Simpirica; Dr. Mroz—Pearl Diver, AO Spine; Dr. Bozic: Agency for Healthcare Research and Quality, National Institutes of Health, Robert Wood Johnson Foundation, California HealthCare Foundation, Center for Health Quality and Innovation, BlueCross BlueShield Association, Integrated Healthcare Association, Pacific Business Group on Health, Ingenix, InVivo Link.2012 Annual Meeting News Tuesday through Friday, February 7 – 10, 2012.
0
骨关节炎病例征集活动火热进行中
19333
骨关节炎病例征集活动火热进行中,欢迎广大骨科医生踊跃参加,主办单位将对记录完整、书写规范的病例进行评选,选出的优秀病例将在“方圆论坛—骨关节炎病例交流高峰会”上进行病例分享。 赶快行动吧!详情请点击骨科在线首页图标或 点击http://www.orthonline.com.cn/tnlbl2011/
0
突破传统 化繁为简 --单纯脊柱矫形成功治疗先天性脊柱侧弯合并脊髓纵裂
10214
     北京协和医院骨科联合麻醉科打破传统,改变过去将先天性脊柱侧弯合并脊髓纵裂患者分两次手术的做法,十余年来成功为124位患者行单纯矫形手术,患者随访结果证实了单纯矫形手术“合二为一”安全、有效。     先天性脊柱侧弯合并脊髓纵裂的外科治疗是脊柱外科医生所面临的挑战性难题。欧美国家的传统观念及既往文献均认为预防性切除骨性纵裂或松解膜性纵裂是治疗这类 先天性脊柱侧弯的关键。因此传统的手术分为两个部分,首先由神经外科打开椎板行后路纵裂骨嵴或纤维膜切除松解,然后由脊柱外科医师在1—2周后进行脊柱侧弯矫形术。这种方法因需多次手术切除骨嵴、纤维膜,椎板切除植骨融合受到影响,术后存在截瘫等并发症及骨嵴再生长的风险。早在1987年,北京协和医院骨科任玉珠教授联合中日友好医院骨科观察7例先天性脊柱侧弯合并脊髓纵裂患者行传统手术疗效后,逐渐加深了对该治疗方法的认识。     回顾文献,有关先天性脊柱侧弯合并脊髓纵裂的自然发展史未见报道。考虑到脊髓纵裂可能终身无症状,沈建雄教授等通过循证医学论证,在国际上较早提出,对未出现神经症状或神经症状稳定的患者,无需一律预防性切除骨嵴或纤维膜,可一次性行脊柱侧弯矫形手术的做法。2000年,骨科在对患者进行脊柱侧弯型、神经功能等详细术前评估的基础上完成了第一例单纯脊柱侧弯矫形术。     截止2010年11月,北京协和医院骨科对124例明确诊断为先天性脊柱侧弯合并脊髓纵裂、且未出现神经症状或神经症状稳定期大于两年的患者行单纯矫形术。并对其中73例患者进行了2年以上随访,平均随访时间为5.3年,所有患者术后矫形均在50%以上,且无一例发生神经系统并发症。以上数据表明协和骨科所行单纯脊柱侧弯矫形手术安全、有效。      该治疗术研究结果分别于2005年加拿大IMAST会议、2008年国际SICOT会议和2010年世界脊柱侧弯学会(SRS)年会上做大会发言,己被亚洲、欧美多数学者所接受。术前CT 显示脊髓纵裂畸形术前CT术前X线患者术前大体相术后X线患者术后大体相 
0

页面

   


骨科在线 北京经纬在线网络科技有限公司

京ICP备15001394号-2 京公网安备11010502051256号

 信息产业部备案管理系统

地址:北京市朝阳区朝阳门北大街乙12号1号楼8层08公寓H

联系电话:010-85615836

Email:orth@orthonline.com.cn